Log in

OTCMKTS:GHIVU - AnPac Bio-Medical Science Stock Price, Forecast & News

$10.63
0.00 (0.00 %)
(As of 02/27/2020 03:47 AM ET)
Today's Range
$10.63
Now: $10.63
$10.63
50-Day Range N/A
52-Week Range
$10.32
Now: $10.63
$10.80
VolumeN/A
Average Volume163,037 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Gores Holdings IV, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, and similar business combination with one or more businesses. The company was incorporated in 2019 and is based in Beverly Hills, California.

Industry, Sector and Symbol

Industry Shell Companies
Sub-IndustryN/A
SectorFinancial Services
Current SymbolOTCMKTS:GHIVU
CUSIPN/A
CIKN/A
WebN/A
Phone310-209-3010

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive GHIVU News and Ratings via Email

Sign-up to receive the latest news and ratings for GHIVU and its competitors with MarketBeat's FREE daily newsletter.


AnPac Bio-Medical Science (OTCMKTS:GHIVU) Frequently Asked Questions

What is AnPac Bio-Medical Science's stock symbol?

AnPac Bio-Medical Science trades on the OTCMKTS under the ticker symbol "GHIVU."

Has AnPac Bio-Medical Science been receiving favorable news coverage?

Headlines about GHIVU stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AnPac Bio-Medical Science earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for AnPac Bio-Medical Science.

Who are some of AnPac Bio-Medical Science's key competitors?

Who are AnPac Bio-Medical Science's key executives?

AnPac Bio-Medical Science's management team includes the folowing people:
  • Mr. Mark R. Stone, Chief Exec. Officer (Age 56)
  • Mr. Andrew McBride, CFO & Sec. (Age 39)

When does the company's quiet period expire?

AnPac Bio-Medical Science's quiet period expires on Wednesday, March 4th. AnPac Bio-Medical Science had issued 40,000,000 shares in its IPO on January 24th. The total size of the offering was $400,000,000 based on an initial share price of $10.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of AnPac Bio-Medical Science?

Shares of GHIVU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AnPac Bio-Medical Science's stock price today?

One share of GHIVU stock can currently be purchased for approximately $10.63.

How can I contact AnPac Bio-Medical Science?

The company can be reached via phone at 310-209-3010.


MarketBeat Community Rating for AnPac Bio-Medical Science (OTCMKTS GHIVU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  4
MarketBeat's community ratings are surveys of what our community members think about AnPac Bio-Medical Science and other stocks. Vote "Outperform" if you believe GHIVU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHIVU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel